Advancing Coronary Bypass Surgery
with State-of-the-Art Technologies
Evidence Based Developments
Coronary bypass surgery (CABG) is the most performed cardiac surgery worldwide. However, both its short- and long-term outcomes are limited. VGS addresses CABGs’ biggest challenges – the poor longevity of vein grafts and procedure related neurological complications.
With robust clinical evidence over the past decade, VGS’s mission is to advance this standard-of-care surgery while focusing on patients’ quality-of-life and reducing the economic burden to healthcare providers.
VIOLA™
Enabling clampless proximal anastomosis
VIOLA novel design allows for optimal hemostasis and construction of multiple aortic anastomoses, without the application of an aortic clamp.
Stroke post CBAG
post CABG
Ani C Anyanwu et al. Epidemiology of stroke after cardiac surgery in the
current era. 2007 Nov;134(5):1121-7. doi: 10.1016/j.jtcvs.2007.06.031.
VEST™
External support for vein grafts in cabg
Randomized clinical trials and real-world data demonstrate that VEST significantly reduces vein graft disease and improves the clinical outcome of CABG.
(P<0.001)
(P<0.001)
Revascularization*
*VEST III RCT: Taggart DP. et al. External Stenting & Disease Progression in Saphenous Vein Grafts Two Years After Coronary Artery Bypass Grafting: A Multicenter Randomized Trial. J Thorac Cardiovasc Surg (2021)
“The results of the VEST III RCT confirm our previous observations regarding the biomechanical effect of external stenting. This is another peak in our continuous journey to improve coronary surgery and patients’ quality of life. It is very satisfactory to see how a combined effort of surgeons, scientists, and innovators matures to technology with high clinical impact”.
Prof. David P. Taggart, Oxford UK,
EACTS Annual Meeting 2019
Surgeons’ perspective
Our interim follow-up data show that at 3 years, clinical and angiographic results are superior compared to those observed in the published randomized trials.”
